TriSalus Life Sciences Inc
NASDAQ:TLSI
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.62
10.25
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one TLSI stock under the Base Case scenario is 4.44 USD. Compared to the current market price of 4.53 USD, TriSalus Life Sciences Inc is Overvalued by 2%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
TriSalus Life Sciences Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for TLSI cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
TriSalus Life Sciences Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
TriSalus Life Sciences Inc
Balance Sheet Decomposition
TriSalus Life Sciences Inc
Current Assets | 27.9m |
Cash & Short-Term Investments | 16.5m |
Receivables | 4.7m |
Other Current Assets | 6.8m |
Non-Current Assets | 4.5m |
PP&E | 3m |
Intangibles | 1.1m |
Other Non-Current Assets | 424k |
Current Liabilities | 12m |
Accounts Payable | 2m |
Accrued Liabilities | 9.7m |
Other Current Liabilities | 328k |
Non-Current Liabilities | 44.6m |
Long-Term Debt | 21.3m |
Other Non-Current Liabilities | 23.3m |
Earnings Waterfall
TriSalus Life Sciences Inc
Revenue
|
24.7m
USD
|
Cost of Revenue
|
-3.1m
USD
|
Gross Profit
|
21.7m
USD
|
Operating Expenses
|
-74.1m
USD
|
Operating Income
|
-52.5m
USD
|
Other Expenses
|
-4.8m
USD
|
Net Income
|
-57.2m
USD
|
Free Cash Flow Analysis
TriSalus Life Sciences Inc
USD | |
Free Cash Flow | USD |
TLSI Profitability Score
Profitability Due Diligence
TriSalus Life Sciences Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
TriSalus Life Sciences Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
TLSI Solvency Score
Solvency Due Diligence
TriSalus Life Sciences Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
TriSalus Life Sciences Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TLSI Price Targets Summary
TriSalus Life Sciences Inc
According to Wall Street analysts, the average 1-year price target for TLSI is 12.16 USD with a low forecast of 10.1 USD and a high forecast of 16.8 USD.
Dividends
Current shareholder yield for TLSI is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
TLSI Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.
Contact
IPO
Employees
Officers
The intrinsic value of one TLSI stock under the Base Case scenario is 4.44 USD.
Compared to the current market price of 4.53 USD, TriSalus Life Sciences Inc is Overvalued by 2%.